Trial Profile
A Randomized, Placebo-Controlled, Parallel Group, Multicenter Study to Evaluate the Efficacy and Safety of Ulipristal Acetate for the Treatment of Abnormal Uterine Bleeding Associated With Leiomyomas
Status:
Completed
Phase of Trial:
Phase III
Latest Information Update: 14 Jan 2020
Price :
$35
*
At a glance
- Drugs Ulipristal (Primary)
- Indications Uterine leiomyoma
- Focus Registrational; Therapeutic Use
- Acronyms Venus I
- Sponsors Actavis; Allergan
- 05 Apr 2019 Results of pooled analysis from VENUS I and II investigating effects of ulipristal acetate on health-related quality of life (QOL) and symptom severity published in the Obstetrics and Gynecology.
- 10 Oct 2018 Results presented at the American Society for Reproductive Medicine Scientific Congress 2018
- 10 Oct 2018 Results assessing the liver safety in women receiving Ulipristal Acetate therapy for Uterine Fibroids in VENUS I and II trials, presented at the American Society for Reproductive Medicine Scientific Congress 2018